Edition:
United Kingdom

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

20.68USD
17 May 2019
Change (% chg)

$-1.05 (-4.83%)
Prev Close
$21.73
Open
$21.32
Day's High
$21.44
Day's Low
$20.62
Volume
83,358
Avg. Vol
81,113
52-wk High
$40.60
52-wk Low
$20.62

Latest Key Developments (Source: Significant Developments)

Akcea Therapeutics Reports Q1 Earnings Per Share $0.34
Wednesday, 8 May 2019 

May 8 (Reuters) - Akcea Therapeutics Inc ::AKCEA REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR FIRST QUARTER 2019.Q1 REVENUE $164 MILLION VERSUS REFINITIV IBES ESTIMATE OF $168.6 MILLION.Q1 EARNINGS PER SHARE $0.34.Q1 EARNINGS PER SHARE ESTIMATE $0.98 -- REFINITIV IBES DATA.RECEIVED MARKETING AUTHORIZATION FOR WAYLIVRA(®) (VOLANESORSEN) IN E.U..AS OF MARCH 31, 2019, AKCEA HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $322 MILLION.  Full Article

Akcea Q3 Loss Per Share $0.73
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Akcea Therapeutics Inc ::AKCEA REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR THIRD QUARTER 2018.QTRLY TOTAL REVENUE $19.2 MILLION VERSUS $9.9 MILLION.QTRLY LOSS PER SHARE $0.73.Q3 EARNINGS PER SHARE VIEW $-0.80 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE VIEW $16.8 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Akcea Therapeutics Inc Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Akcea Therapeutics Inc ::AKCEA THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Akcea Therapeutics To Reduce Its Workforce By About 10 Pct
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Akcea Therapeutics Inc ::AKCEA THERAPEUTICS INC - INTENDS TO REDUCE ITS WORKFORCE BY APPROXIMATELY 10%.AKCEA THERAPEUTICS - UNDER REORGANIZATION PLAN, EXPECTS TO INCUR Q3 RESTRUCTURING CHARGES IN THE RANGE OF $2.0 MILLION TO $2.5 MILLION.AKCEA THERAPEUTICS INC - ENACTED A PLAN TO REORGANIZE ITS WORKFORCE FOLLOWING FDA ISSUANCE OF CRL FOR ITS NEW DRUG APPLICATION FOR WAYLIVRA.  Full Article

Akcea And Ionis Receive Complete Response Letter For Waylivra From FDA
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Akcea Therapeutics Inc ::AKCEA AND IONIS RECEIVE COMPLETE RESPONSE LETTER FOR WAYLIVRA FROM FDA.AKCEA AND IONIS RECEIVE COMPLETE RESPONSE LETTER FOR WAYLIVRA FROM FDA.AKCEA THERAPEUTICS INC - " FEEL STRONGLY" THAT WAYLIVRA DEMONSTRATES A FAVORABLE BENEFIT/RISK PROFILE IN PEOPLE WITH FCS.  Full Article

Akcea Posts Q4 Loss Per Share $0.35
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Akcea Therapeutics Inc ::AKCEA REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR FOURTH QUARTER AND YEAR END 2017.Q4 LOSS PER SHARE $0.35.  Full Article

Akcea Initiates Phase 2b Study Of Hypertriglyceridemia And Established Heart Disease Treatment
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Akcea Therapeutics Inc ::AKCEA INITIATES PHASE 2B STUDY OF AKCEA-APOCIII-LRX IN PATIENTS WITH HYPERTRIGLYCERIDEMIA AND ESTABLISHED CARDIOVASCULAR DISEASE.AKCEA THERAPEUTICS INC - ‍ ANTICIPATES REPORTING TOP-LINE DATA FROM PHASE 2B OF AKCEA-APOCIII-L(RX)​ STUDY IN 2019.  Full Article

Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Akcea Therapeutics Inc :Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS.Akcea Therapeutics Inc - ‍in U.S., Food And Drug Administration assigned a prescription drug user fee act goal date of August 30, 2018​.Akcea Therapeutics Inc - marketing applications for Volanesorsen been accepted for review in U.S., EU & Canada for treatment of patients with FCS.  Full Article

Akcea initiates AKCEA-ANGPTL3-LRx Phase 2 program in patients with rare hyperlipidemias
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Akcea Therapeutics Inc :Akcea initiates AKCEA-ANGPTL3-LRx Phase 2 program in patients with rare hyperlipidemias.Akcea Therapeutics Inc - ‍AKCEA-ANGPTl3-L(Rx )is designed to reduce production of angiopoietin-like 3, or ANGPTL3​.  Full Article

Akcea Therapeutics Q3 loss per share $0.27
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Akcea Therapeutics Inc :Q3 loss per share $0.27.Akcea Therapeutics Inc qtrly ‍revenue $13.4 million​.Q3 earnings per share view $-0.19, revenue view $11.9 million -- Thomson Reuters I/B/E/S.  Full Article

EU committee approves Akcea-Ionis drug for rare genetic disease

March 1 An advisory committee of the European Medicines Agency (EMA) on Friday recommended conditionally approving a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals Inc that aims to treat a rare genetic disease that causes fat accumulation in the blood.